Viridian Therapeutics Posts $24.7 Million in Lumvoa Net Product Revenue for Q3 2026
Photo: TokenPost
Viridian Therapeutics generated $24.7 million in Lumvoa net product revenue during the third quarter of 2026, while total revenue reached $25.752 million for the period ended Sept. 30. Net loss per common share was $0.81 on both basic and diluted bases. The results were released Nov. 4 and covered the three months ended Sept. 30, 2026. John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.
Source: TokenPost
